Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,465,178

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.

Derek Lewis headshot

Invest Like Warren Buffett With These 3 Stocks

The Oracle of Omaha has been on the offensive in 2022, recognizing value in a challenging market.

Neogen (NEOG) Finalizes Food Safety Business Merger With 3M

The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.

SmileDirectClub (SDC) Faces Low Aligner Shipment, Margin Woe

The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.

Here's Why You Should Retain Change Healthcare (CHNG) Stock

Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.

CVS Health (CVS) to Buy Signify Health, Grow in Home Healthcare

According to CVS Health (CVS), Signify Health, as a leading healthcare platform, will play a critical role in advancing the company's healthcare services strategy.

Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care

Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.

Here's Why You Should Hold on to BD (BDX) Stock for Now

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.

Nalak Das headshot

S&P 500 Likely to Trade Rangebound in September: 5 Picks

We have narrowed our search to five S&P 500 stocks that have popped year to date despite the index's bloodbath. These are: ADM, CTVA, MCK, MPC and XOM.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.

Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight

Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.

Masimo's (MASI) Latest Watch to Improve Patient Outcomes

Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.

Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail

Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.

Here's Why You Should Retain Haemonetics (HAE) Stock Now

Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.

Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail

Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.

McKesson (MCK) Up 7.7% Since Last Earnings Report: Can It Continue?

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates

Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.

3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Hold on to Chemed (CHE) Stock Now

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.

Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton

Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.

Boston Scientific (BSX) Grows Operationally Amid Macro Issues

In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.

Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates

Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.

Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates

Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.

Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY23 View

Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both of its segments.